Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling the company to proceed with Phase 2 clinical development of its first-in-class multiple sclerosis (MS) candidate. The upcoming trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, utilizing both clinical and radiological measures. Site selection is underway, and the company aims to begin patient enrollment and drug administration as soon as possible.
The significance of this FDA clearance lies in Lucid-MS's unique mechanism of action. Unlike existing MS therapies that primarily modulate the immune system, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, the process by which the protective myelin sheath around nerve fibers is damaged. The drug targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown, offering a potential disease-modifying approach that could address the underlying neurodegeneration in MS.
Quantum BioPharma reported that Lucid-MS exhibited a favorable safety profile and was well tolerated in prior Phase 1 trials involving healthy participants. The company also stated it holds more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may support the advancement of the program.
This development is important because multiple sclerosis affects millions worldwide, and current treatments often focus on reducing immune attacks but do not directly promote myelin repair. If Lucid-MS proves effective in Phase 2, it could represent a paradigm shift in MS treatment, offering hope for slowing or even reversing disability progression. The FDA's clearance validates the preclinical data and moves the candidate closer to potential clinical use.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focusing on the research and development of Lucid-MS as its lead compound. For more information, visit the full press release and the company's newsroom.
